Exabis Library
Welcome to the e-CCO Library!
P328: Ustekinumab is an effective and safe therapy in anti-TNF refractory Crohn’s Disease: a two year real-life observational study from Spain
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P329 ECCO grant recipient: preliminary results of the HOT-TOPIC trial (Hyperbaric Oxygen Therapy for the Treatment Of Perianal fistulas In Crohn’s disease)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P329: Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P329: Comparative Assessment of Adalimumab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P329: Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P329: Infliximab biosimilar in the treatment of inflammatory bowel disease: a Japanese single-cohort observational study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P329: Stool multiplex molecular PCR assay in comparison to conventional stool tests for detecting gastrointestinal infections as cause of flares in Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P329: Utility of faecal calprotectin to assess Crohn’s disease activity in patients with an ileostomy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P329: Which should come first? Surgery or biologic therapy for ileocaecal Crohn’s disease in biologic naïve patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P330 Inflammatory Bowel Disease (IBD) patients frequently report adverse drug reactions during biologic therapy: A multicentre, prospective, patient-reported pharmacovigilance monitoring system
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P330: A national survey on therapeutic education in inflammatory bowel disease by an association of caregivers and expert patients: French Association for Therapeutic Education in inflammatory bowel disease (AFEMI)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P330: A prospective trial to evaluate the feasibility of a mobile app in patients with inflammatory bowel disease under maintenance therapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P330: Discontinuation of corticosteroids among ulcerative colitis patients treated with vedolizumab in the United States
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P330: Immunity in patients with inflammatory bowel disease on biologic therapy after COVID 19 vaccination
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P330: Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBD
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P330: Ultrasound remission after biologic induction predicts long-term endoscopic remission in Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P330: Vitamin D insufficiency in patients with inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P331 Productivity loss in patients with inflammatory bowel disease receiving treatment for iron deficiency anaemia: A comparison of ferric maltol and IV iron
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
Wednesday, 3 March 2021, 4:12 PM by Dauren Ramankulov
P331: Allopurinol and azathioprine co-therapy or thioguanine dose splitting: shifting the shunters in the mercaptopurine pathway in a paediatric inflammatory bowel disease population—a single-centre experience
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P331: Composite outcomes in Crohn’s disease: a systematic review and meta-analysis of observational studies
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM